June 29, 2020 / 7:48 AM / a month ago

BRIEF-GSK’S Daprodustat Gains First Regulatory Approval

June 29 (Reuters) - GlaxoSmithKline PLC:

* GLAXOSMITHKLINE PLC - GSK’S DAPRODUSTAT GAINS FIRST REGULATORY APPROVAL

* GLAXOSMITHKLINE PLC - GSK’S DAPRODUSTAT GAINS FIRST REGULATORY APPROVAL

* GSK - APPROVAL MARKS A SIGNIFICANT STEP IN GSK’S GLOBAL EFFORTS TO HELP PATIENTS WITH ANAEMIA DUE TO CHRONIC KIDNEY DISEASE (CKD).

* GSK - APPROVAL MARKS A SIGNIFICANT STEP IN GSK’S GLOBAL EFFORTS TO HELP PATIENTS WITH ANAEMIA DUE TO CHRONIC KIDNEY DISEASE

* GSK - APPROVAL OF A JAPANESE NEW DRUG APPLICATION (JNDA) FOR DUVROQ TABLETS, AN ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR (HIF-PHI)

* GSK - ONGOING PHASE III GLOBAL PROGRAMME WILL SUPPORT ADDITIONAL REGULATORY SUBMISSIONS ACROSS WORLD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below